Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | PNLIP | P16233 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523838 | 0.91 | LMNA (0.63) | LMNAMEN1KMT2AKDM4ETP53 | |
| SCHEMBL8405384 | 0.86 | LMNA (0.69) | LMNAMEN1KMT2AKDM4ETP53 | |
| SCHEMBL2915874 | 0.86 | LMNA (0.60) | LMNAMEN1KMT2AKDM4ETP53 | |
| SCHEMBL18327174 | 0.82 | LMNA (0.89) | LMNAMEN1KMT2AKDM4ETP53 | |
| SCHEMBL7623651 | 0.82 | LMNA (0.60) | LMNAMEN1KMT2AKDM4ETP53 | |
| SCHEMBL8579300 | 0.81 | NR1H4 (0.73) | LMNAMEN1KMT2AKDM4EHTT | |
| SCHEMBL28719803 | 0.81 | MEN1 (0.86) | LMNAMEN1KMT2AKDM4ETP53 | |
| Salicylanilide SCHEMBL14051034 | 0.81 | MEN1 (1.00) | LMNAMEN1KMT2AKDM4ETP53 | |
| Salicylanilide SCHEMBL20165864 | 0.81 | MEN1 (1.00) | LMNAMEN1KMT2AKDM4ETP53 | |
| Salicylanilide SCHEMBL152221 | 0.81 | MEN1 (1.00) | LMNAMEN1KMT2AKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873667-B2 | Arylsulfanyl compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873667-B2 | Arylsulfanyl compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-1100522-B1 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-1100522-B1 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9345722-B2 | Pharmaceutical formulations for the treatment of alzheimer's disease | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| EP-1372667-B1 | COMPOSITIONS FOR DELIVERING BISPHOSPHONATES | EMISPHERE TECH INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-1372667-B1 | COMPOSITIONS FOR DELIVERING BISPHOSPHONATES | EMISPHERE TECH INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20030072740-A1 | Pulmonary delivery of active agents | EMISPHERE TECHNOLOGIES, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1100522-A4 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002070438-A2 | COMPOSITIONS FOR DELIVERING BISPHOSPHONATES | EMISPHERE TECHNOLOGIES, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6440929-B1 | ACYLATED AMINO ACID OR A SULFONATED AMINO ACID | EMISPHERE TECHNOLOGIES, INC. | 2002-08-27 | — | — | US | disclosed |
| CN-1311686-A | Pulmonary delivery of active agents | EMISPHERE TECH INC (US) | 2001-09-05 | — | — | CN | disclosed |
| EP-1100771-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1100522-A1 | PULMONARY DELIVERY OF ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006534-A9 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000006534-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006184-A1 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072740-A1 | Pulmonary delivery of active agents | ANXA11, ANXA1, PIGS | LMNA 1649/4885MEN1 4418/4885KMT2A 3542/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | LMNA 4376/4885MEN1 3557/4885KMT2A 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.